Skip to main navigation

Contact Us

Investor Relations

Our Company
Product Candidates
- Pipeline
- MultiTAA Therapies
Our Science
Clinical Trials
- Active Clinical Trials
- Expanded Access Policy
Investors/Media
Careers

Investors/Media

Press Releases

Press Releases

Year

May 04, 2022

Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting

Apr 26, 2022

Marker Therapeutics Announces Entry into Services Agreement with Wilson Wolf

Mar 17, 2022

Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results

Mar 07, 2022

Marker Therapeutics to Present at Two Upcoming March Investor Conferences

Feb 16, 2022

Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion

Feb 08, 2022

Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022

Jan 19, 2022

Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer

Dec 09, 2021

Marker Therapeutics Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors

Nov 18, 2021

Marker Therapeutics Announces that Data from Investigator-Sponsored Phase 1 Study With its MultiTAA-Specific T Cells to be Presented at the 2021 American Society of Hematology Annual Meeting

Nov 10, 2021

Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results

Pagination

First page
Previous page
Page 1
Page 2
Current page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 21 - 30 of 92

Investors/Media

Investors/Media Home
News & Events
- Press Releases
- Events & Presentations
Stock Information
Financials & Filings
Corporate Governance
Investor Resources

IR and Media Contacts

investor.relations@markertherapeutics.com
(713) 400-6400

©2023 Marker Therapeutics, Inc. All Rights Reserved.

Footer Links

Sitemap
Terms of Use
Privacy Policy